Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 in Recurrent High-Grade Gliomas
NCT01380782Phase 2Completed
- Start
- May 2012
- Primary completion
- Jul 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of nintedanib in glioma. Primary endpoint: 6-Month Progression-Free Survival. Started May 2012; status: completed.
02
Drugs
nintedanib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT01380782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01380782.